CytomX Therapeutics, Inc.
$2.69
-$0.51 (-15.94%)
$2.67Day Range$3.21
Key Statistics
Market Cap
$586.15M
Shares Outstanding
217.9M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Oct 8, 2015
Round Lot
100
Locale
US
Trading Data
Day Open
$3.20
Day High
$3.21
Day Low
$2.67
Volume
7.51M
VWAP
$2.80
Prev Close
$3.20
Transactions
--
Acc. Volume
--
About CytomX Therapeutics, Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
PHARMACEUTICAL PREPARATIONSSIC 283469 employees151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080650.515.3185IPO Oct 8, 2015US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001501989
- Composite FIGI
- BBG001J472L3
- Share Class FIGI
- BBG001V0GS49
- Ticker Root
- CTMX
- SIC Code
- 2834
About CytomX Therapeutics, Inc. (CTMX) Stock
CytomX Therapeutics, Inc. (CTMX) closed the 2026-09-15 session at $2.69, down 15.94% versus the previous close (-0.51). The stock opened at $3.20 and traded between $2.67 and $3.21 during that session. Session trading volume was 7.5M shares. The volume-weighted average price (VWAP) is $2.80.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
CytomX Therapeutics, Inc. has a market capitalization of $586.1 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. CTMX is listed on the XNAS exchange. The company employs approximately 69 people. CytomX Therapeutics, Inc. is headquartered in SOUTH SAN FRANCISCO, CA. The recorded listing date is 2015-10-08.
On this page you can find market CTMX stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.